Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Shuai Xia; Meiqin Liu; Chao Wang; Wei Xu; Qiaoshuai Lan; Siliang Feng; Feifei Qi; Linlin Bao; Lanying Du; Shuwen Liu; Chuan Qin; Fei Sun; Zhengli Shi; Yun Zhu; Shibo Jiang; Lu Lu

The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.09.983247 doi: bioRxiv preprint Cytotoxicity assay 586 Cytotoxicity of the peptides to the cells (Vero-E6, Huh-7, LLC-MK2 and RD cells) 587 was tested by using the Cell Counting Kit-8 (CCK-8). Briefly, each cell type was 588 seeded into the wells of a 96-well microtiter plate (10,000 per well) and incubated at 589 37 °C for 12-15 h, replacing medium with DMED containing EK1C4 at graded 590 concentrations to culture at 37 °C for 2 days; CCK-8 solution (10 μL per well) was was predicted by SWISS-MODEL sever 39 using 6XLT as reference for EK1 moiety, 627 and by Autodock 4 software 40 for cholesterol moiety (Fig. S8) . References 638 author/funder. All rights reserved. No reuse allowed without permission.